Health Rounds: Older breast cancer patients using estrogen cream live longer, study finds
June 4 (Reuters) - In older women diagnosed with breast cancer, use of estrogen creams to treat menopause symptoms was not only safe but was also linked with longer survival in a large U.S. study.
Use of the hormone creams by postmenopausal breast cancer survivors was associated with a lower risk of disease progression, recurrence, or death, rather than an increased risk as had been feared, researchers reported, opens new tab at the ASCO meeting.
Vaginal estrogen creams help with menopause symptoms such as vaginal dryness, discomfort, and pain during intercourse, but breast cancer survivors often avoid these products over concern they might stimulate breast cancer cells that use hormones to grow.
Researchers reviewed national database records on 18,620 female breast cancer patients aged 65 and older who were diagnosed between 2010-2017, including 800 who used vaginal estrogen creams.
After accounting for patients' race, cancer stage, treatments and other factors, the researchers saw a statistically significant increase in overall survival among patients who used vaginal estrogen. The cream users also had a significant increase in breast cancer-specific survival – the interval from diagnosis to death from breast cancer.
On average, estrogen cream users had a 47% lower risk of dying from breast cancer and a 44% lower risk of death from any cause during the study period, compared to non-users.
Even in patients whose tumors were known to use hormones for growth, estrogen cream use was associated with a 38% lower risk of death from any cause. Estrogen cream users with hormone-positive breast cancer also had a lower risk of death from breast cancer, but that difference was not statistically significant.
Use of the creams for more than seven years appeared to confer an additional survival benefit.
'These findings add to a rising contemporary paradigm shift that local hormone therapy is not associated with increased risk to overall or breast cancer-specific survival, which has important clinical implications,' the researchers said.
Cannabis use does not worsen outcomes of patients receiving immunotherapy cancer drugs such as Merck's (MRK.N), opens new tab Keytruda or Opdivo from Bristol Myers Squibb (BMY.N), opens new tab, according to data, opens new tab presented at the ASCO meeting.
In what researchers say is the largest study so far looking at the effect of cannabis on patients starting cancer treatment with the drugs also known as immune checkpoint inhibitors, there was no difference between users and non-users either in length of survival or length of survival without complications.
'Cannabis is known to be anti-inflammatory and immunosuppressive in laboratory studies, which is why it is a concern... as it may cancel out the immune-stimulating effects of immunotherapy,' said study leader Dr. Song Yao of Roswell Park Comprehensive Cancer Center in Buffalo, New York.
Yao and colleagues recruited 1,666 patients, most with advanced cancer, who were starting treatment with one of these immunotherapies.
About 17% said they regularly used cannabis. During follow-up lasting up to 31 months, with a median, 10.4 months, their cannabis use remained fairly steady.
The researchers are not advising patients who aren't using cannabis to consider starting.
'But for patients who are using cannabis to manage cancer symptoms or treatment side effects, our study shows that use of cannabis or cannabinoid products will not lessen the effectiveness of immune checkpoint inhibitor therapy,' Yao said.
The study looked only at immune checkpoint inhibitors, and the results would not necessarily be the same for other cancer treatments, he noted.
'It's really important for immunocompromised patients - a group that includes many people in active treatment for cancer - to discuss any use of cannabis or CBD products with their physicians and to use these products only with caution, as cannabis products may increase the risk of infection or interfere with the metabolism of immunosuppressants,' Yao said.
(To receive the full newsletter in your inbox for free sign up here)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
2 days ago
- The Guardian
Key takeaways from world's largest cancer conference in Chicago
Doctors, scientists and researchers shared new findings on ways to tackle cancer at the 2025 American Society of Clinical Oncology annual meeting, the world's largest cancer conference. The event in Chicago, attended by about 44,000 health professionals, featured more than 200 sessions on this year's theme, Driving Knowledge to Action: Building a Better Future. Here is a roundup of the key studies. An immunotherapy drug could help some cancer patients live years longer without the disease getting worse or coming back, a trial found. Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years, compared to 30 months with standard care. It also cut the risk of the disease returning in another part of the body. A second study showed people with a deadly form of skin cancer could live longer with an innovative one-time immunotherapy. Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, the trial found. Car T-cell therapy is a new form of immunotherapy where a patient's own T-cells – a type of white blood cell – are tweaked in a lab to target and kill cancer cells. The designer cells are then infused back into their bloodstream to fight the disease. One trial found cancer patients treated by Car T-cell therapy can live 40% longer. The therapy has already proved successful in treating blood cancers. Now results from the world's first randomised controlled trial of Car T-cell therapy in solid tumours suggest it could be transformative in the fight against these cancers too. Solid tumours represent about 90% of all cancers, including breast, lung and pancreatic cancer. In the trial hailed as a 'milestone' by experts, patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer treated with Car T-cell therapy lived on average about 40% longer than patients who received standard care. A second Car T-cell therapy shrank tumours in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported in Chicago. 'Seeing recurrent [glioblastoma] tumours shrink like this is extraordinary, because the immunotherapy drugs that we've tried in the past have been unable to do that,' said the study's lead author, Dr Stephen Bagley, of the University of Pennsylvania. In a world first, doctors announced at the conference that thousands of cancer patients in England would benefit from a DNA blood test that saves lives by fast-tracking them on to personalised treatments. The liquid biopsy looks for circulating tumour DNA (ctDNA) to find specific genetic variations of cancer. The NHS will offer it to patients with lung and breast cancer – two of the most common forms of the disease. Rapid results mean patients can immediately be offered drugs and treatments specifically tailored to the genetic profile of their disease, significantly increasing their survival chances and paving the way for a new era of precision medicine. Exercise slashes the risk of death in cancer patients by more than a third, a landmark trial found. Physical activity could also prevent the disease coming back and stop new tumours developing, as well as lifting mood, reducing fatigue and boosting strength. The world's first randomised clinical trial to specifically evaluate if a structured exercise regime after treatment could reduce the risk of recurrence or new cancers in patients took place over more than a decade. Hailed as gamechanging by experts, the results show it could. The trial found patients had a 37% lower risk of death and a 28% lower risk of their cancer coming back or new cancers developing, compared with patients who received only health advice. 'When we saw the results, we were just astounded,' said the study's lead author, Dr Christopher Booth, of Queen's University in Kingston, Canada. Margaret Tubridy was one of 889 patients with colon cancer recruited to the trial from six countries – the UK, US, Australia, France, Canada and Israel. Five years after her diagnosis, she told the Guardian she was now free of cancer and healthy, with no signs of the disease coming back. Amid a series of breakthroughs aimed at tackling the most common cancer in women, doctors were told a new drug can stop some breast cancer tumours before they grow. A trial showed that camizestrant stops cancer cells from using hormones to grow, which helps patients stay well longer and delays the need for chemotherapy. It was the first global study to show that using blood tests to find early signs of cancer resistance to treatment helps patients. The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases. Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with standard therapies. 'This is going to be very impactful for our patients,' said Dr Hope Rugo, the head of breast medical oncology at City of Hope hospital in Duarte, California. A second trial found that a new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further chemotherapy and helps patients live longer. Artificial intelligence could help end a 'postcode lottery' for a life-extending treatment for prostate cancer, researchers said. Abiraterone is a hormone therapy described as a 'gamechanger' that works by blocking the production of testosterone, which fuels prostate cancer growth. It has already helped hundreds of thousands with advanced prostate cancer to live longer. But some countries, including England, have stopped short of offering the 'spectacular' drug more widely to men whose disease has not spread. A team from the US, UK and Switzerland have built an AI test that shows which men would most likely benefit from abiraterone. The breakthrough will enable healthcare systems to roll out the drug to more men, and spare others unnecessary treatment.
Reuters
2 days ago
- Reuters
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
June 6 (Reuters) - The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's ( opens new tab popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition. Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday. The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes. The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance. It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare". The U.S. Food and Drug Administration did not immediately respond to a Reuters request for comment.
Reuters
2 days ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)
